Skip to main content

Advertisement

SpringerLink
Log in

Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

The role of bevacizumab in metastatic breast cancer is controversial. Identification of predictive biomarkers could help to select patients who really benefit from it. We evaluated the association of angiogenesis-related gene polymorphisms with the treatment outcome of bevacizumab in metastatic breast cancer patients.

Patients and methods

eNOS-786T/C and -894G/T, IL-8-251T/A genomic polymorphisms were assessed in 31 metastatic breast cancer patients treated with bevacizumab plus chemotherapy in the first-line setting. Testing for association between each polymorphism and treatment outcome was performed.

Results

Patients with IL-8 251 AA genotype showed a significantly lower progression-free survival in each combination comparison: “TT” vs “AA” (13 vs 8 months; p = 0.008); TT vs TA vs AA (13 vs 11 vs 8 months; p = 0.02); TT vs TA +AA (13 vs 11 months; p = 0.01); TT + TA vs AA (12 vs 8 months; p = 0.01) and a lower overall survival when compared with TT +TA genotype (26 vs 51 months, p = 0.04). Patients carrying eNOS 894 TT genotype showed a statistically significant lower progression-free survival than patients with GG genotype (11.5 vs 26.5 months; p = 0.04) with no differences in the overall survival. No association with response rate was found with any of the polymorphisms analyzed.

Conclusion

These findings suggest that IL-8 251T/A and eNOS-894 G/T polymorphisms might have a role in predicting treatment outcome of bevacizumab in metastatic breast cancer. Our results are hypothesis generating and need to be confirmed in larger clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

    Article  PubMed  CAS  Google Scholar 

  2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  PubMed  CAS  Google Scholar 

  3. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502–8.

    Article  PubMed  CAS  Google Scholar 

  4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.

    Article  PubMed  Google Scholar 

  5. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.

    Article  PubMed  CAS  Google Scholar 

  6. Miles DW. Bevacizumab in breast cancer: fundamental questions remain. Lancet Oncol. 2013;14(2):99–101. doi:10.1016/S1470-2045(13)70012-3.

    Article  PubMed  Google Scholar 

  7. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  PubMed  CAS  Google Scholar 

  8. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966–72. doi:10.1200/JCO.2008.21.6630.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–47. doi:10.1200/JCO.2008.21.6457.

    Article  PubMed  CAS  Google Scholar 

  10. Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, et al. RIBBON-1:randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2009;27:s15.

    Article  Google Scholar 

  11. O’Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2008;8(4):370–3. doi:10.3816/CBC.2008.n.045.

    Article  PubMed  Google Scholar 

  12. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29(32):4286–93. doi:10.1200/JCO.2010.34.1255.

    Article  PubMed  CAS  Google Scholar 

  13. Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Ann Oncol. 2011;22(3):595–602. doi:10.1093/annonc/mdq430.

    Article  PubMed  CAS  Google Scholar 

  14. Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011; doi:10.1186/1756-9966-30-54.

    PubMed  PubMed Central  Google Scholar 

  15. Miles DW, Diéras V, Cortés J, Duenne AA, Yi J, O’Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013 [Epub ahead of print].

  16. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122(1):1–7. doi:10.1007/s10549-009-0727-0.

    Article  PubMed  CAS  Google Scholar 

  17. Rose S. FDA pulls approval for avastin in breast cancer. Cancer Discov. 2011;1(7):OF1–2. doi:10.1158/2159-8290.CD-ND112311OL-08.

    Google Scholar 

  18. Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res. 2013;19(11):2824–7. doi:10.1158/1078-0432.CCR-12-3409.

    Article  PubMed  CAS  Google Scholar 

  19. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108(5):1052–60. doi:10.1038/bjc.2013.69.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, et al. Prognostic and predictive value of tumor VEGF gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013;19(5):1281–9. doi:10.1158/1078-0432.CCR-12-3029.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Kümler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev. 2014;40(8):960–73.

    Article  PubMed  Google Scholar 

  23. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008;14(22):7554–63. doi:10.1158/1078-0432.CCR-08-0351.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258(5089):1798–801.

    Article  PubMed  CAS  Google Scholar 

  25. Varney ML, Olsen KJ, Mosley RL, Bucana CD, Talmadge JE, Singh RK. Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: a paracrine role of tumor-associated macrophages in tumor angiogenesis. In Vivo. 2002;16(6):471–7.

    PubMed  CAS  Google Scholar 

  26. Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med. 2005;11(9):992–7.

    PubMed  CAS  Google Scholar 

  27. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70(3):1063–71. doi:10.1158/0008-5472.CAN-09-3965.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Gyanchandani R, Sano D, Ortega Alves MV, Klein JD, Knapick BA, Oh S, Myers JN, et al. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol. 2013;49(8):761–70. doi:10.1016/j.oraloncology.2013.03.452.

    Article  PubMed  CAS  Google Scholar 

  29. Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J, et al. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer. 2012;107:287–90.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Hautamaki a, Kivioja J, Vavuli S, Kakko S, Savolainen ER, Savolainen MJ et al. Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. Retina. 2013 [Epub ahead of print].

  32. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 2000;55:1023–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  33. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012;92(4):503–10. doi:10.1038/clpt.2012.136.

    PubMed  CAS  Google Scholar 

  34. Ando M. Nephrotoxicity—proteinuria and hypertension—. Gan To Kagaku Ryoho. 2008;35(10):1649–53.

    PubMed  CAS  Google Scholar 

  35. Perlik M, Seremak-Mrozikiewicz A, Barlik M, Kurzawińska G, Kraśnik W, Drews K. Genetic variants of eNOS in gestational hypertension and pre-eclampsia. Ginekol Pol. 2012;83(9):652–9.

    PubMed  Google Scholar 

  36. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20(2):227–30. doi:10.1093/annonc/mdn637.

    Article  PubMed  CAS  Google Scholar 

  37. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphism and breast cancer susceptibility and prognosis. Eur J Immunogenet. 2004;31:167–73.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Clinical Oncology, Catholic University of the Sacred Heart, L.go F. Vito 1, 00168, Rome, Italy

    M. Di Salvatore, L. Lo Giudice, E. Rossi, G. Nazzicone, M. G. Rodriquenz, S. Cappuccio, A. Inno, P. Fuso, A. Orlandi, A. Strippoli, A. Astone, A. Cassano & C. Barone

  2. Laboratory of Clinical Molecular Biology, Institute of Biochemistry and Clinical Biochemistry, Catholic University of the Sacred Heart, L.go F. Vito 1, 00168, Rome, Italy

    C. Santonocito & E. Capoluongo

  3. Medical Oncology, Sacro Cuore Don Calabria Hospital, Via Don A. Sempreboni 5, 37024, Negrar, VR, Italy

    A. Inno

Authors
  1. M. Di Salvatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Lo Giudice
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Santonocito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Nazzicone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. G. Rodriquenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Cappuccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Inno
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Fuso
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Orlandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Strippoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E. Capoluongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Astone
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Cassano
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. C. Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Di Salvatore.

Ethics declarations

Conflict of interest

All authors declare that they do not have any conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Salvatore, M., Lo Giudice, L., Rossi, E. et al. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. Clin Transl Oncol 18, 40–46 (2016). https://doi.org/10.1007/s12094-015-1334-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1334-7

Keywords

Search

Navigation